Stabilised, synthetic sulforaphane in hospitalized patients with suspected COVID-19 pneumonia: a double-blind, placebo-controlled RCT
H. Abo-Leyah (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), R. Hull (Sheffield, United Kingdom), H. Keir (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), D. Alferes De Lima (Dundee, United Kingdom), B. New (Dundee, United Kingdom), S. Inglis (Dundee, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), A. Dinkova-Kostova (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2610
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Abo-Leyah (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), R. Hull (Sheffield, United Kingdom), H. Keir (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), D. Alferes De Lima (Dundee, United Kingdom), B. New (Dundee, United Kingdom), S. Inglis (Dundee, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), A. Dinkova-Kostova (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom). Stabilised, synthetic sulforaphane in hospitalized patients with suspected COVID-19 pneumonia: a double-blind, placebo-controlled RCT. 2610
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|